clinical trial · NCT07399730
Ravulizumab Outcomes in Polish Patients With aHUS
AstraZeneca·—·not yet recruiting·n = 80
Atypical Hemolytic Uremic SyndromeRavulizumab
brief summary
This multicenter, observational cohort study uses retrospective collection of past medical history and prospective follow-up to capture longitudinal data on the management and clinical outcomes of patients with atypical hemolytic uremic syndrome (aHUS) treated with ravulizumab as part of routine clinical practice under Poland's National Drug Program (NDP).
started
Apr 1, 2026
primary completion
Dec 31, 2030
completion
Dec 31, 2030
last updated
Feb 10, 2026
official title
A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol